医学
耐受性
特应性皮炎
瘙痒的
皮肤病科
不利影响
内科学
作者
Katlein França,Jana Hercogová,Massimo Fioranelli,Serena Gianfaldoni,Anastasiya Atanasova Chokoeva,Georgi Tchernev,Uwe Wollina,Michael Tirant,P Bayer,Maria Coburn,Paul J. Anderson,Bryan J. Donnelly,Tara Kennedy,J Gaibor,Meenakshi Arora,L Clews,František Novotný,Massimo Fioranelli,Georgi Konstantinov Maximov,Torello Lotti
出处
期刊:PubMed
日期:2016-08-09
卷期号:30 (2 Suppl 3): 55-63
被引量:1
摘要
Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinex®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinex®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinex®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinex®) product family is a safe and effective treatment option for AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI